Donate

News

Latest news

Article of the week: Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN

June 3, 2020,

Multiple Myeloma Research Review

May 29, 2020

Australian clinicians report on real world use of bortezomib in elderly MM patients

May 22, 2020

Article of the week: Once-versus twice-weekly car fi lzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis

May 22, 2020,

Daratumumab and Hyaluronidase-fihj Approved For Patients With Myeloma

May 18, 2020

Cell Protein Analysis May Predict Multiple Myeloma Response to Treatment

May 12, 2020

COVID-19’s Impact on How Patients with CLL, Myeloma Have Received Treatment

May 5, 2020

Newsletter: Autumn 2020

May 4, 2020

Blood cancer patients at most risk from COVID-19 compared to other cancers

April 28, 2020

Spain Reviewing Trial to Treat COVID-19 Pneumonia With Myeloma Therapy Aplidin

April 24, 2020

Genetic Test Could Determine Patients With Ultra High Risk Multiple Myeloma

April 21, 2020

First case of COVID-19 in a patient with multiple myeloma

April 16, 2020

Genetic Test Identifies Ultra-High-Risk Myeloma Patients

April 14, 2020

WEBINAR: Leading experts to give their views on treating multiple myeloma patients during the COVID-19 pandemic

April 14, 2020

First Report of MM Patient Successfully Treated for COVID-19 With Tocilizumab

April 9, 2020

Ygalo Shows Positive Response in Triple-refractory Multiple Myeloma Trial

April 7, 2020

The squeeze on healthcare in locked-down New Zealand

April 6, 2020

Treating COVID-19 in a patient with multiple myeloma

April 6, 2020

Pharmac widens funding for lenalidomide for those with blood cancer

April 2, 2020

An open letter to the Prime Minister of New Zealand, Jacinda Ardern

April 1, 2020

Covid 19 coronavirus: Pharmac eases restrictions on cancer drugs during Covid-19 pandemic

April 1, 2020

Kiwis with incurable blood cancer set to receive newly reimbursed treatment option

April 1, 2020

New drug could reverse treatment resistance in advanced multiple myeloma

March 30, 2020

Article of the week: Managing haematology and oncology patients during the COVID-19 pandemic

March 25, 2020,

Information About COVID-19 for Myeloma Patients

March 23, 2020

Coronavirus in NZ: How to self-isolate – Kiwi diagnosed with cancer shares advice

March 18, 2020

National Research Cancer Institute UK Confirms Benefit Molecular Profiling in Multiple Myeloma

March 18, 2020

Myeloma and the Coronavirus

March 9, 2020

Multiple Myeloma Research Review

February 26, 2020

New CAR T-cell Therapy Shows Early Promise Against Multiple Myeloma in Lab Study

February 25, 2020

Organ responses with daratumumab therapy in previously treated AL amyloidosis

February 17, 2020

Sanofi Partners to Develop Diagnostic Test for Multiple Myeloma Patients on Potential Therapy

January 28, 2020

ALCYONE Update: Adding Daratumumab to VMP Improves Survival in Transplant-Ineligible Myeloma

January 23, 2020

Cancer drug funding welcomed

January 17, 2020

Newsletter: January 2020

January 16, 2020

Myeloma NZ calls on Pharmac to make good on access deal

January 14, 2020

Pharmac to widen treatment access for myeloma – New Zealand’s second most common blood cancer

December 20, 2019

Multiple Myeloma Research Review

December 12, 2019

Drug Previously Thought to Treat Alzheimer Shows Potential in Multiple Myeloma

December 5, 2019

Cancer Control Agency open, Prime Minister hails Blair Vining’s ‘tireless advocacy’

December 3, 2019

Major developments in multiple myeloma to be presented at ASH

December 3, 2019

Myeloma Medicines Applications: The status of medicines applications for myeloma currently with Pharmac

December 2, 2019

Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis

November 21, 2019

Petition for Patient Voice Aotearoa: Reform Pharmac and double the Pharmac budget

November 18, 2019

FDA Approves Daratumumab-Based Quadruplet Regimen for Transplant-Eligible Myeloma

November 18, 2019

Submission on the draft Cancer Action Plan 2019-2029

November 15, 2019

Prophylactic antibiotics could benefit patients with newly diagnosed myeloma

November 11, 2019

Funding Medicines in New Zealand: Revision of the Medicines waiting list to 30 June 2019

November 5, 2019

Impact of age, sex, ethnicity, socio-economic deprivation and novel pharmaceuticals on the overall survival of patients with multiple myeloma in New Zealand

November 5, 2019,

In pursuit of improved outcomes in high-risk multiple myeloma 

November 1, 2019